Oral immunization with recombinant Lactobacillus plantarum induces a protective immune response in mice with lyme disease

Clinical and Vaccine Immunology

Volumn 15, Issue 9, 2008, Pages 1429-1435

  Del Rio, Beatriz ^a   Dattwyler, Raymond J ^a,b   Aroso, Miguel ^a   Neves, Vera ^a   Meirelles, Luciana ^a   Seegers, Jos F M L ^c   Gomes Solecki, Maria ^a,b,d  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Biopeptides Corp   (United States)

^c Falco Biotherapeutics BV   (Netherlands)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTOBACILLUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BORRELIA BURGDORFERI; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LACTOBACILLUS PLANTARUM; LYME DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BLOOD; BORRELIA BURGDORFERI; DISEASE VECTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HEART; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IXODES; LACTOBACILLUS PLANTARUM; LYME DISEASE; LYME DISEASE VACCINES; MICE; MICE, INBRED C3H; URINARY BLADDER;

EID: 51649091939     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00169-08     Document Type: Article

References (63)

1. Anderson, R., G. Dougan, and M. Roberts. 1996. Delivery of the pertactin/P69 polypeptide of Bordetella pertussis using an attenuated Salmonella typhimurium vaccine strain: expression levels and immune response. Vaccine 14:1384-1390.
2. Ascon, M. A., D. M. Hone, N. Walters, and D. W. Pascual. 1998. Oral immunization with a Salmonella typhimurium vaccine vector expressing recombinant enterotoxigenic Escherichia coli K99 fimbriae elicits elevated antibody titers for protective immunity. Infect. Immun. 66:5470-5476.
3. Braat, H., E. C. de Jong, J. M. van den Brande, M. L. Kapsenberg, M. P. Peppelenbosch, E. A. van Tol, and S. J. van Deventer. 2004. Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function. J. Mol. Med. 82:197-205.
4. + T cells via modulation of dendritic cell function. Am. J. Clin. Nutr. 80:1618-1625.
5. Brown, E. L., J. H. Kim, E. S. Reisenbichler, and M. Hook. 2005. Multicomponent Lyme vaccine: three is not a crowd. Vaccine 23:3687-3696.
6. Cazorla, S. I., P. D. Becker, F. M. Frank, T. Ebensen, M. J. Sartori, R. S. Corral, E. L. Malchiodi, and C. A. Guzman. 2008. Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect. Immun. 76:324-333.
7. Chang, Y. F., M. J. Appel, R. H. Jacobson, S. J. Shin, P. Harpending, R. Straubinger, L. A. Patrican, H. Mohammed, and B. A. Summers. 1995. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect. Immun. 63:3543-3549.
8. Chen, J., J. A. Field, L. Glickstein, P. J. Molloy, B. T. Huber, and A. C. Steere. 1999. Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheum. 42:1813-1822.
9. Cortes-Perez, N. G., F. Lefevre, G. Corthier, K. Adel-Patient, P. Langella, and L. G. Bermudez-Humaran. 2007. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 25:6581-6588.
10. de Silva, A. M., S. R. Telford III, L. R. Brunet, S. W. Barthold, and E. Fikrig. 1996. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J. Exp. Med. 183:271-275.
11. de Vos, W. M. 2005. Lactic acid bacteria: genetics, metabolism and application. FEMS Microbiol. Rev. 29:391.
12. Earnhart, C. G., E. L. Buckles, and R. T. Marconi. 2007. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains. Vaccine 25:466-480.
13. Earnhart, C. G., and R. T. Marconi. 2007. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences. Hum. Vaccin. 3:281-289.
14. Echchannaoui, H., M. Bianchi, D. Baud, M. Bobst, J. C. Stehle, and D. Nardelli-Haefliger. 2008. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect. Immun. 76:1940-1951.
15. Erickson, K. L., and N. E. Hubbard. 2000. Probiotic immunomodulation in health and disease. J. Nutr. 130:403S-409S.
16. Fikrig, E., S. W. Barthold, F. S. Kantor, and R. A. Flavell. 1992. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect. Immun. 60:773-777.
17. Fikrig, E., S. W. Barthold, F. S. Kantor, and R. A. Flavell. 1991. Protection of mice from Lyme borreliosis by oral vaccination with Escherichia coli expressing OspA. J. Infect. Dis. 164:1224-1227.
18. Fikrig, E., S. R. Telford DT, S. W. Barthold, F. S. Kantor, A. Spielman, and R. A. Flavell. 1992. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc. Natl. Acad. Sci. USA 89:5418-5421.
19. Gilmore, R. D., Jr., R. M. Bacon, A. M. Carpio, J. Piesman, M. C. Dolan, and M. L. Mbow. 2003. Inability of outer-surface protein C (OspC)-primed mice to elicit a protective anamnestic immune response to a tick-transmitted challenge of Borrelia burgdorferi. J. Med. Microbiol. 52:551-556.
20. Gilmore, R. D., Jr., K. J. Kappel, M. C. Dolan, T. R. Burkot, and B. J. Johnson. 1996. Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect. Immun. 64:2234-2239.
21. Gomes-Solecki, M. J., D. R. Brisson, and R. J. Dattwyler. 2006. Oral vaccine that breaks the transmission cycle of the Lyme disease spirochete can be delivered via bait. Vaccine 24:4440-4449.
22. Grangette, C., H. Muller-Alouf, M. Geoffroy, D. Goudercourt, M. Turneer, and A. Mercenier. 2002. Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. Vaccine 20:3304-3309.
23. Grangette, C., H. Muller-Alouf, D. Goudercourt, M. C. Geoffroy, M. Turneer, and A. Mercenier. 2001. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect. Immun. 69:1547-1553.
24. Gross, D. M., T. Forsthuber, M. Tary-Lehmann, C. Etling, K. Ito, Z. A. Nagy, J. A. Field, A. C. Steere, and B. T. Huber. 1998. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281:703-706.
25. Hagman, K. E., X. Yang, S. K. Wikel, G. B. Schoeler, M. J. Caimano, J. D. Radolf, and M. V. Norgard. 2000. Decor in-binding protein A (DbpA) of Borrelia burgdorferi is not protective when immunized mice are challenged via tick infestation and correlates with the lack of DbpA expression by B. burgdorferi in ticks. Infect. Immun. 68:4759-4764.
26. Hanniffy, S. B., A. T. Carter, E. Hitchin, and J. M. Wells. 2007. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J. Infect. Dis. 195:185-193.
27. Kajikawa, A., E. Satoh, R. J. Leer, S. Yamamoto, and S. Igimi. 2007. Intragastric immunization with recombinant Lactobacillus casei expressing flagellar antigen confers antibody-independent protective immunity against Salmonella enterica serovar Enteritidis. Vaccine 25:3599-3605.
28. Karlsson, H., P. Larsson, A. E. Wold, and A. Rudin. 2004. Pattern of cytokine responses to gram-positive and gram-negative commensal bacteria is profoundly changed when monocytes differentiate into dendritic cells. Infect. Immun. 72:2671-2678.
29. Kim, Y. G., T. Ohta, T. Takahashi, A. Kushiro, K. Nomoto, T. Yokokura, N. Okada, and H. Danbara. 2006. Probiotic Lactobacillus casei activates innate immunity via NF-κB and p38 MAP kinase signaling pathways. Microbes Infect. 8:994-1005.
30. Kohler, J. J., L. Pathangey, A. Hasona, A. Progulske-Fox, and T. A. Brown. 2000. Long-term immunological memory induced by recombinant oral Salmonella vaccine vectors. Infect. Immun. 68:4370-4373.
31. Lee, J. S., H. Poo, D. P. Han, S. P. Hong, K. Kim, M. W. Cho, E. Kim, M. H. Sung, and C. J. Kim. 2006. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J. Virol. 80:4079-4087.
32. Li, Y. G., F. L. Tian, F. S. Gao, X. S. Tang, and C. Xia. 2007. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus. Vaccine 25:902-911.
33. Link-Amster, H., F. Rochat, K. Y. Saudan, O. Mignot, and J. M. Aeschlimann. 1994. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol. Med. Microbiol. 10:55-63.
34. Luke, C. J., R. C. Huebner, V. Kasmiersky, and A. G. Barbour. 1997. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Vaccine 15:739-746.
35. Maassen, C. B., J. D. Laman, M. J. den Bak-Glashouwer, F. J. Tielen, J. C. van Holten-Neelen, L. Hoogteijling, C. Antonissen, R. J. Leer, P. H. Pouwels, W. J. Boersma, and D. M. Shaw. 1999. Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragrnent C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Vaccine 17:2117-2128.
36. Macpherson, A. J., and N. L. Harris. 2004. Interactions between commensal intestinal bacteria and the immune system. Nat. Rev. Immunol. 4:478-485.
37. Makarova, K. S., and E. V. Koonin. 2007. Evolutionary genomics of lactic acid bacteria. J. Bacteriol. 189:1199-1208.
38. Mannam, P., K. F. Jones, and B. L. Geller. 2004. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect. Immun. 72:3444-3450.
39. Marco, M. L., R. S. Bongers, W. M. de Vos, and M. Kleerebezem. 2007. Spatial and temporal expression of Lactobacillus plantarum genes in the gastrointestinal tracts of mice. Appl. Environ. Microbiol. 73:124-132.
40. Mestecky, J., M. W. Russell, and C. O. Elson. 2007. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J. Immunol. 179:5633-5638.
41. Mohamadzadeh, M., S. Olson, W. V. Kalina, G. Ruthel, G. L. Demmin, K. L. Warfield, S. Bavari, and T. R. Klaenhammer. 2005. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl. Acad. Sci. USA 102:2880-2885.
42. Moorthy, G., and R. Ramasamy. 2007. Mucosal immunisation of mice with malaria protein on lactic acid bacterial cell walls. Vaccine 25:3636-3645.
43. Oozeer, R., N. Goupil-Feuillerat, C. A. Alpert, M. van de Guchte, J. Anba, J. Mengaud, and G. Corthier. 2002. Lactobacillus casei is able to survive and initiate protein synthesis during its transit in the digestive tract of human flora-associated mice. Appl. Environ. Microbiol. 68:3570-3574.
44. Perdigon, G., S. Alvarez, and A. Pesce de Ruiz Holgado. 1991. Immunoadjuvant activity of oral Lactobacillus casei: influence of dose on the secretory immune response and protective capacity in intestinal infections. J. Dairy Res. 58:485-496.
45. + T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag. J. Immunol. 170:5176-5187.
46. Pouwels, P. H., R. J. Leer, and W. J. Boersma. 1996. The potential of Lactobacillus as a carrier for oral immunization: development and preliminary characterization of vector systems for targeted delivery of antigens. J. Biotechnol. 44:183-192.
47. Pouwels, P. H., A. Vriesema, B. Martinez, F. J. Tielen, J. F. Seegers, R. J. Leer, J. Jore, and E. Smit. 2001. Lactobacilli as vehicles for targeting antigens to mucosal tissues by surface exposition of foreign antigens. Methods Enzymol. 336:369-389.
48. Probert, W. S., and R. B. LeFebvre. 1994. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect. Immun. 62:1920-1926.
49. Schwan, T. G., and J. Piesman. 2000. Temporal changes in outer surface proteins A and C of the Lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice. J. Clin. Microbiol. 38:382-388.
50. Schwan, T. G., J. Piesman, W. T. Golde, M. C. Dolan, and P. A. Rosa. 1995. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc. Natl. Acad. Sci. USA 92:2909-2913.
51. Seegers, J. F. 2002. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol. 20:508-515.
52. + T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 20:623-629.
53. Shaw, D. M., B. Gaerthe, R. J. Leer, J. G. Van Der Stap, C. Smittenaar, M. Heijne Den Bak-Glashouwer, J. E. Thole, F. J. Tielen, P. H. Pouwels, and C. E. Havenith. 2000. Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. Immunology 100:510-518.
54. H-1 type response by immunoactive AT oligonucleotide from lactic acid bacteria via Toll-like receptor 9 signaling. Biochem. Biophys. Res. Commun. 326:782-787.
55. Steere, A. C., V. K. Sikand, F. Meurice, D. L. Parenti, E. Fikrig, R. T. Schoen, J. Nowakowski, C. H. Schmid, S. Laukamp, C. Buscarino, D. S. Krause, et al. 1998. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N. Engl. J. Med. 339:209-215.
56. Sudo, N., S. Sawamura, K. Tanaka, Y. Aiba, C. Kubo, and Y. Koga. 1997. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J. Immunol. 159:1739-1745.
57. Veckman, V., M. Miettinen, J. Pirhonen, J. Siren, S. Matikainen, and I. Julkunen. 2004. Streptococcus pyogenes and Lactobacillus rhamnosus differentially induce maturation and production of Th1-type cytokines and chemokines in human monocyte-derived dendritic cells. J. Leukoc Biol. 75:764-771.
58. Wells, J. M., and A. Mercenier. 2008. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Microbiol. 6:349-362.
59. Willett, T. A., A. L. Meyer, E. L. Brown, and B. T. Huber. 2004. An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc. Natl. Acad. Sci. USA 101:1303-1308.
60. Wu, C. M., and T. C. Chung. 2007. Mice protected by oral immunization with Lactobacillus reuteri secreting fusion protein of Escherichia coli enterotoxin subunit protein. FEMS Immunol. Med. Microbiol. 50:354-365.
61. Xie, C., J. S. He, M. Zhang, S. L. Xue, Q. Wu, X. D. Ding, W. Song, Y. Yuan, D. L. Li, X. X. Zheng, Y. Y. Lu, and Z. Shang. 2007. Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum. Gene Ther. 18:746-752.
62. Xu, Y., and Y. Li. 2007. Induction of immune responses in mice after intragastric administration of Lactobacillus casei producing porcine parvovirus VP2 protein. Appl. Environ. Microbiol. 73:7041-7047.
63. Yang, X., B. J. Hinnebusch, T. Trunkle, C. M. Bosio, Z. Suo, M. Tighe, A. Harmsen, T. Becker, K. Crist, N. Walters, R. Avci, and D. W. Pascual. 2007. Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J. Immunol. 178:1059-1067.